ArticleBMC cancer2021

Assessment of various continual reassessment method models for dose-escalation phase 1 oncology clinical trials: using real clinical data and simulation studies.

G D James et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.